Company intelligence / Profile preview
Livionex
Los Gatos, California, United Stateslivionex.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Livionex has reported positive end-of-phase 2 results with its C-KAD eye drop for early-to-moderate cataracts and is preparing to advance to Phase 3 trials. Its LIVFRESH toothpaste is approved in Europe and commercially available. The company’s technology platform targets metal ions implicated in disease pathways such as oxidative stress and inflammation. Other programs are at preclinical or early clinical stages.
- Therapeutic areas
- OtherOphthalmologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeDevice (for oral care products/toothpaste)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaborations with major US universities; specific partners not named publiclyNo major pharma partnerships disclosed.
Beyond the preview
Go deeper on Livionex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Livionex.